In this episode, we explore benzodiazepine use disorder, distinguishing between physical dependence and addiction while examining practical strategies for safe prescribing. Did you know only 1.5% of benzodiazepine users actually develop a use disorder?

Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide
• Benzodiazepine Use Disorder

In this episode, we explore the potential role of the probiotic Akkermansia muciniphila in managing olanzapine-induced weight gain. Could this tiny gut bacterium be the key to maintaining metabolic health while on antipsychotics?

Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.5 CME: Quick Take Vol. 67
• Olanzapine-Induced Weight Gain: Can Akkermansia Muciniphila Help?

In this episode, we explore the dangerous risks of benzodiazepine use, focusing on the potentially lethal combination with opioids, cognitive impairment, increased accident risk, and fall hazards. Did you know that benzodiazepines combined with opioids increase overdose risk fivefold in the first 90 days?

Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide
• Understanding the Major Risks of Benzodiazepine Use

In this episode, we explore the latest research on antidepressant discontinuation symptoms, revealing that about 14% of patients experience these effects when stopping medication. Which antidepressants are most likely to cause these "brain zaps" and other withdrawal symptoms?

Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.5 CME: Quick Take Vol. 67
• Which Antidepressants Have the Highest Risk of Discontinuation Symptoms?

In this episode, we discuss the appropriate use of benzodiazepines, focusing on evidence-based indications and optimal medication selection. Did you know that alprazolam has unique properties that make it more addictive than other benzodiazepines?

Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide
• Appropriate Benzodiazepine Use: Indications and Optimal Selection

In this episode, we explore the evidence behind Transcranial Magnetic Stimulation (TMS) for depression, from early clinical trials to real-world effectiveness. What makes some patients respond better to TMS than others? We discuss response rates, treatment protocols, and the exciting development of faster treatment options.

Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices
• Exploring the Evidence of TMS for Depression

In this episode, we explore the crucial aspects of patient selection for Transcranial Magnetic Stimulation (TMS) in treating depression. We discuss insurance criteria, contraindications, and practical considerations. Did you know that while TMS was FDA-approved in 2008, it wasn't widely accessible until Medicare began covering it in 2014?

Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices
• Optimizing Patient Selection for TMS Treatment

In this episode, we explore a landmark Finnish study examining the long-term risk of agranulocytosis in patients taking clozapine. The research followed 62,000 patients over 22 years, providing crucial data about this rare but serious side effect. Could these findings change how we approach clozapine prescribing and monitoring requirements?

Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.75 CME: Quick Take Vol. 66
• Does Clozapine's Agranulocytosis Risk Persist Beyond Initial Treatment Period?

In this episode, we explore Transcranial Magnetic Stimulation (TMS) as a treatment option for Obsessive-Compulsive Disorder (OCD). We discuss the FDA-approved devices, unique protocols, and why patients need their anxiety triggered before each session. Did you know TMS for OCD targets a completely different brain region than TMS for depression?

Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices
• Exploring the Evidence of TMS for OCD

In this episode, we explore donanemab, a groundbreaking monoclonal antibody treatment for Alzheimer's disease. We discuss its efficacy in reducing beta-amyloid plaques, unique treatment duration protocol, and safety considerations. Could this time-limited treatment approach revolutionize how we manage Alzheimer's progression?

Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.75 CMEs: Quick Take Vol. 66
• Can Donanemab Slow Alzheimer's Progression?